Further characterization of this SLE subpopulation with high serum NET may allow for a more individualized approach to treatment with the potential to target proinflammatory processes (such as IL-1 inhibitor or IL-6 inhibitor) rather than antibody-dependent processes (such as CD20-specific antibody or antibody against B-cell activating factor) in this group of patients. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.